GlassScriptPhysician profile
John B Shelton
NPI 1083688964
$2,207.82
in general payments reported to CMS, 2019-2025
34 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2021: $19.53 · 2022: $61.50 · 2023: $80.04 · 2024: $503 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $305.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $281.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $222.72 | 2019-2025 | |
| Glaxosmithkline, LLC. | $156.49 | 2019 | |
| Amgen INC. | $111.79 | 2019 | |
| Lilly USA, LLC | $96.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $82.11 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $72.53 | 2019-2024 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $69.60 | 2019-2025 | |
| Corium, LLC | $57.53 | 2024 | Azstarys |
| Shire North American Group INC | $56.39 | 2019 | |
| Axsome Therapeutics, INC. | $52.38 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $51.48 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $50.34 | 2024-2025 | |
| Astellas Pharma US INC | $48.34 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $46.49 | 2019 | |
| Amarin Pharma, INC. | $44.22 | 2019 | |
| Abbvie INC. | $42.41 | 2022-2025 | |
| Dexcom, INC. | $39.59 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.81 | 2019 | |
| Inspire Medical Systems, INC. | $36.57 | 2023-2024 | Inspire |
| Jazz Pharmaceuticals INC. | $30.23 | 2019 | |
| Cochlear Americas | $29.76 | 2024 | Baha, Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Acadia Pharmaceuticals INC | $24.93 | 2024 | Daybue |
| Takeda Pharmaceuticals U.S.A., INC. | $22.87 | 2019 | |
| Tris Pharma INC | $21.75 | 2019 | |
| Collegium Pharmaceutical, INC. | $20.60 | 2025 | Jornay Pm |
| Kowa Pharmaceuticals America, INC. | $16.78 | 2024 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.46 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.40 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.19 | 2019 | |
| Organon LLC | $11.61 | 2025 | Nexplanon |
| Allergan, INC. | $11.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Shelton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.